CN110914267B - 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用 - Google Patents

嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用 Download PDF

Info

Publication number
CN110914267B
CN110914267B CN201880047588.2A CN201880047588A CN110914267B CN 110914267 B CN110914267 B CN 110914267B CN 201880047588 A CN201880047588 A CN 201880047588A CN 110914267 B CN110914267 B CN 110914267B
Authority
CN
China
Prior art keywords
methyl
amino
pyrimidin
phenyl
methylpiperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880047588.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110914267A (zh
Inventor
丁克
丁健
申佳奕
耿美玉
陆小云
谢华
孙敏
宗在伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Jinan University
Jiangsu Aosaikang Pharmaceutical Co Ltd
Original Assignee
Shanghai Institute of Materia Medica of CAS
Jinan University
Jiangsu Aosaikang Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS, Jinan University, Jiangsu Aosaikang Pharmaceutical Co Ltd filed Critical Shanghai Institute of Materia Medica of CAS
Publication of CN110914267A publication Critical patent/CN110914267A/zh
Application granted granted Critical
Publication of CN110914267B publication Critical patent/CN110914267B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880047588.2A 2017-07-19 2018-07-17 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用 Active CN110914267B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017105916446 2017-07-19
CN201710591644 2017-07-19
PCT/CN2018/096009 WO2019015593A1 (fr) 2017-07-19 2018-07-17 Composé de pyrimidopyridone ou pyridopyridone et utilisation correspondante

Publications (2)

Publication Number Publication Date
CN110914267A CN110914267A (zh) 2020-03-24
CN110914267B true CN110914267B (zh) 2022-07-12

Family

ID=65014945

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880047588.2A Active CN110914267B (zh) 2017-07-19 2018-07-17 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用

Country Status (2)

Country Link
CN (1) CN110914267B (fr)
WO (1) WO2019015593A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112010844B (zh) * 2019-05-31 2023-07-25 中国药科大学 N-(嘧啶-2-基)香豆素-7-胺衍生物作为蛋白激酶抑制剂的制法和应用
CN114286678A (zh) * 2019-08-23 2022-04-05 北京泰德制药股份有限公司 抑制并诱导降解egfr和alk的化合物
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
CN113121574B (zh) * 2019-12-31 2023-02-17 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的用途
WO2021139775A1 (fr) * 2020-01-10 2021-07-15 江苏先声药业有限公司 Composé de pyridone et son application
CN116514726B (zh) * 2022-01-28 2025-06-10 四川大学 嘧啶类衍生物及其用途
CN115353514B (zh) * 2022-08-31 2023-07-25 河南师范大学 氟代吡啶并嘧啶酮类化合物及其合成方法
CN118005633B (zh) * 2024-01-09 2025-09-02 五邑大学 一种用于检测苏氨酸酪氨酸激酶的荧光探针及其制备方法和应用
CN118084902B (zh) * 2024-01-16 2024-10-29 赣南师范大学 2-氨基噻唑嘧啶并吡啶酮类化合物或药学上可接受的盐或立体异构体及制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063415A2 (fr) * 2009-11-23 2011-05-26 Afraxis, Inc. Méthodes de traitement de trouble cognitif léger
CN102648200A (zh) * 2009-10-09 2012-08-22 亚弗克希斯公司 用于治疗cns病症的8-乙基-6-(芳基)吡啶并[2，3-d]嘧啶-7(8h)-酮
WO2013086451A2 (fr) * 2011-12-09 2013-06-13 Afraxis, Inc. Inhibiteurs de pak destinés au traitement du cancer
CN104418860A (zh) * 2013-08-20 2015-03-18 中国科学院广州生物医药与健康研究院 嘧啶并杂环类化合物及其药用组合物和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
WO2013043232A2 (fr) * 2011-04-08 2013-03-28 Afraxis, Inc. 8-éthyl-6(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones utilisables en vue du traitement d'affections touchant le système nerveux, ainsi qu'en vue du traitement du cancer
CN105307657B (zh) * 2013-03-15 2020-07-10 西建卡尔有限责任公司 杂芳基化合物和其用途
PT3102577T (pt) * 2014-02-07 2018-10-23 Principia Biopharma Inc Derivados de quinolona como inibidores do recetor do fator de crescimento de fibroblastos
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102648200A (zh) * 2009-10-09 2012-08-22 亚弗克希斯公司 用于治疗cns病症的8-乙基-6-(芳基)吡啶并[2，3-d]嘧啶-7(8h)-酮
WO2011063415A2 (fr) * 2009-11-23 2011-05-26 Afraxis, Inc. Méthodes de traitement de trouble cognitif léger
WO2013086451A2 (fr) * 2011-12-09 2013-06-13 Afraxis, Inc. Inhibiteurs de pak destinés au traitement du cancer
CN104418860A (zh) * 2013-08-20 2015-03-18 中国科学院广州生物医药与健康研究院 嘧啶并杂环类化合物及其药用组合物和应用

Also Published As

Publication number Publication date
WO2019015593A1 (fr) 2019-01-24
CN110914267A (zh) 2020-03-24

Similar Documents

Publication Publication Date Title
CN110914267B (zh) 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用
CN102816162B (zh) 嘧啶并嘧啶酮类化合物及其药用组合物和应用
EP3339294B1 (fr) Quinolone, sel pharmaceutiquement acceptable, ou stéréoisomère de celui-ci comme inhibiteur de axl
CN103012399B (zh) 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用
CN113166110B (zh) 2-氨基嘧啶类化合物及其应用
CN117642408A (zh) 含硒杂环类化合物及其药用组合物和应用
KR20130043175A (ko) 헤테로사이클릭 알키닐 벤젠 화합물 및 의약 조성물 및 그들의 용도
CN105189514A (zh) 作为bet-蛋白抑制剂用于治疗过度增殖性疾病的吡咯并-和吡唑并-三唑并二氮杂卓
JP7621624B2 (ja) ２－アミノピリミジン系化合物、その医薬組成物、及び使用
CN110305161A (zh) 2-氨基嘧啶类化合物及其应用
WO2022253283A1 (fr) Agent de dégradation de protéine kinases et son utilisation
US20230348462A1 (en) Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
CN112313213A (zh) 3-氨基吡唑类化合物及其应用
CN103374000B (zh) 嘧啶并二氮杂卓类化合物及其药用组合物和应用
AU2019241374B2 (en) Quinoline or quinazoline compound and application thereof
CN110437220B (zh) 三氮唑类化合物及其应用
WO2023233033A1 (fr) Nouveaux inhibiteurs de par-2
CN112851667B (zh) 含氮并杂环类化合物及其药用组合物和应用
WO2021180008A1 (fr) Composé cyclique tri-aromatique contenant une structure d'urée et utilisation associée
WO2015193228A1 (fr) 1,4-dihydropyrido[3,4-b]pyrazinones inhibitrices de protéine bet, à groupe éther ou amino aromatique para-substitué
CN103570731B (zh) 嘧啶并三环或嘧啶并四环类化合物及其药用组合物和应用
CN118084902B (zh) 2-氨基噻唑嘧啶并吡啶酮类化合物或药学上可接受的盐或立体异构体及制备方法和应用
CN115348963B (zh) 吡啶并嘧啶类化合物及其应用
WO2024153077A1 (fr) Inhibiteur de hpk1, son procédé de préparation et son utilisation
CN120590384A (zh) 吡啶并[2,3-d]嘧啶-7（8h）-酮衍生物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant